Business UpdateMay 21, 2026, 06:08 AM
NanoViricides Discusses Ebola Drug Candidates at AGP Showcase
AI Summary
NanoViricides, Inc. participated in the Alliance Global Partners Healthcare Companies Showcase, where Dr. Anil R. Diwan discussed the company's drug candidates for the Ebolavirus epidemic in the Democratic Republic of Congo (DRC). He highlighted NV-387, a broad-spectrum antiviral entering Phase II trials for Mpox in DRC, and NV-387 encapsulating Remdesivir as a backup. Both candidates are expected to be effective against the current Bundibugyo strain of Ebolavirus. The company also noted its existing clinical site in DRC for Mpox patients.
Key Highlights
- NanoViricides participated in the Alliance Global Partners (AGP) Healthcare Companies Showcase on May 20, 2026.
- Dr. Anil R. Diwan discussed the company's drug candidates for the Ebolavirus epidemic in DRC.
- NV-387, a broad-spectrum antiviral, is entering Phase II clinical trial against Mpox in DRC.
- NV-387 encapsulating Remdesivir is a back-up candidate.
- Both candidates are expected to be effective against the current Ebola virus Bundibugyo strain in DRC.
- Remdesivir was previously found active against Ebola in animal models and safe in humans.
- The company developed an oral formulation of remdesivir by encapsulating it in NV-387 nanoviricide micelles.
- NanoViricides has a clinical site in DRC for treatment of Mpox patients.
Price Impact
More from NNVC